ReShape Lifesciences (RSLS) announced that the Company has received a Notice of Allowance from the U.S. Patent and Trademark Office, USPTO, for patent application 17/046,677, entitled, “Simultaneous Multi-Site Vagus Nerve Modulation for Improved Glycemic Control System and Methods.” When issued, the patent will provide protection until April 12, 2039. The Diabetes Neuromodulation system leverages its proprietary vagus nerve block technology platform, along with vagus nerve stimulation, to treat Type 2 diabetes, a prominent disorder linked with obesity.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RSLS:
- ReShape Lifesciences signs distribution agreement with Liaison Medical
- ReShape Lifesciences Announces Securities Purchase Agreement
- ReShape Lifesciences 2.6M share Secondary priced at $2.33
- ReShape Lifesciences granted key IP in Israel
- ReShape Lifesciences files to sell common stock, no amount given